<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056952</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2009/15</org_study_id>
    <nct_id>NCT01056952</nct_id>
  </id_info>
  <brief_title>Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure (OPTIFLOW)</brief_title>
  <official_title>Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess, in patients with acute hypoxemic respiratory failure, the
      short term physiologic effects of the high flow oxygen nasal therapy (Optiflow), in term of
      inspiratory muscle effort, gas exchange, comfort and dyspnea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The administration of a known concentration of oxygen is an important part of routine care of
      the patient admitted in intensive care unit for acute hypoxemic respiratory failure. A new
      high flow oxygen delivery system (Fisher and Paykel Health care) has been developed
      (Optiflow). The system used a heated humidifier and heated breathing circuit via a nasal
      interface. High flow nasal therapy (Optiflow) is associated with the generation of
      significant positive airway pressure in healthy volunteers. Positive expiratory pressure may
      have a number of benefits in respiratory failure which include improved ventilation/perfusion
      matching with improved oxygenation, reduced airways resistance and reduced work of breathing.
      Moreover high flow nasal therapy may improve oxygen administration by decreasing oxygen
      dilution, decreasing death space and using high levels of humidification
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inspiratory muscle effort : oesophageal pressure (Poes) and the oesophageal pressure time product (PTPoes)</measure>
    <time_frame>Every 30 minutes for 90 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gas exchange :PaO2/FiO2 ratio</measure>
    <time_frame>Every 30 minutes for 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort assessed using a five-item semi quantitative scale</measure>
    <time_frame>Every 30 minutes for 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea assessed using a visual analogic scale</measure>
    <time_frame>Every 30 minutes for 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Optiflow then CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP then Optiflow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>O2stand</intervention_name>
    <description>Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 &gt; 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)</description>
    <arm_group_label>CPAP then Optiflow</arm_group_label>
    <arm_group_label>Optiflow then CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher &amp; Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 &gt; 90%. A facial mask composed of a transparent mask and a soft inflatable will be used</description>
    <arm_group_label>CPAP then Optiflow</arm_group_label>
    <arm_group_label>Optiflow then CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optiflow</intervention_name>
    <description>High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 &gt; 90%</description>
    <arm_group_label>Optiflow then CPAP</arm_group_label>
    <arm_group_label>CPAP then Optiflow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio of 300 mm Hg or less
             after breathing oxygen

          -  The presence of lung infiltrates on a posteroanterior chest radiograph

        Exclusion Criteria:

          -  Face or cranial trauma or surgery

          -  Patients younger than 18 years

          -  History of COPD

          -  Acute respiratory acidosis (defined as a pH &lt;7.30 and a PaCO2 &gt;50 mm Hg)

          -  Hemodynamic instability with arterial pressure &lt; 90mmHg

          -  Respiratory instability with PaO2/FiO2&lt;100mmHg

          -  ventricular arrhythmias

          -  Excess respiratory secretions.

          -  Upper gastrointestinal bleeding

          -  Recent gastric or oesophageal surgery

          -  Tracheostomy or other airways disorders

          -  Pneumothorax

          -  Contraindication of gastric probe insertion

          -  Impossibility to insert the oesophageal probe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric VARGAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pellegrin Hospital, Recovery Unit</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

